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Differential Time Trends of Outcomes and Costs of Care for Acute
Myocardial Infarction Hospitalizations by ST Elevation and Type of
Intervention in the United States, 2001–2011
Takehiro Sugiyama, MD, MSHS, PhD; Kohei Hasegawa, MD, MPH; Yasuki Kobayashi, MD, PhD; Osamu Takahashi, MD, MPH, PhD;
Tsuguya Fukui, MD, MPH; Yusuke Tsugawa, MD, MPH
Background-—Little is known whether time trends of in-hospital mortality and costs of care for acute myocardial infarction (AMI)
differ by type of AMI (ST-elevation myocardial infarction [STEMI] vs. non-ST-elevation [NSTEMI]) and by the intervention received
(percutaneous coronary intervention [PCI], coronary artery bypass grafting [CABG], or no intervention) in the United States.
Methods and Results-—We conducted a serial cross-sectional study of all hospitalizations for AMI aged 30 years or older using the
Nationwide Inpatient Sample, 2001–2011 (1 456 154 discharges; a weighted estimate of 7 135 592 discharges). Hospitalizations
were stratified by type of AMI and intervention, and the time trends of in-hospital mortality and hospital costs were examined for
each combination of the AMI type and intervention, after adjusting for both patient- and hospital-level characteristics. Compared
with 2001, adjusted in-hospital mortality improved significantly for NSTEMI patients in 2011, regardless of the intervention
received (PCI odds ratio [OR] 0.68, 95% CI 0.56 to 0.83; CABG OR 0.57, 0.45 to 0.72; without intervention OR 0.61, 0.57 to 0.65).
As for STEMI, a decline in adjusted in-hospital mortality was significant for those who underwent PCI (OR 0.83; 0.73 to 0.94);
however, no significant improvement was observed for those who received CABG or without intervention. Hospital costs per
hospitalization increased significantly for patients who underwent intervention, but not for those without intervention.
Conclusions-—In the United States, the decrease in in-hospital mortality and the increase in costs differed by the AMI type and the
intervention received. These non-uniform trends may be informative for designing effective health policies to reduce the health and
economic burdens of AMI. ( J Am Heart Assoc. 2015;4:e001445 doi: 10.1161/JAHA.114.001445)
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B oth the incidence
1–11 of and in-hospital mortality1–7,12–15
from acute myocardial infarctions (AMI), particularly
ST-elevation AMI (STEMI), has declined in the United States
during the last decade. Regardless of such improvements in
disease management, AMI remains the leading cause of death
in the United States.12 Several studies have examined the time
trend in the clinical outcome (eg, in-hospital mortality rate,
30-day mortality rate) and costs of care for AMI both at
regional and national levels.1–9,13–18 But to the best of our
knowledge, no study has evaluated whether time trend differs
by the type of AMI and the intervention the patients received.
In this context, we examined whether the time trends for in-
hospital mortality and hospital costs for AMI hospitalizations
differ by the type of AMI and the intervention performed during
hospitalization from 2001 to 2011 using nationally represen-
tative data of AMI hospitalizations in the United States.
Methods
Design and Settings
We conducted a serial cross-sectional analysis of hospitaliza-
tions from 2001 through 2011, using the Healthcare Cost and
Utilization Project (HCUP) Nationwide Impatient Sample
(NIS).19 The NIS is a stratified, single-stage cluster sample,
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which represents one of the largest all-payer inpatient care
data in the United States. NIS samples approximately 8
million hospital discharges per year from hospitals in those
states participating in HCUP (eg, NIS 2011—1045 hospitals
from 46 states). NIS offers a weight variable and study design
variables that enable production of national estimates and
their variances of all hospitalizations in the United States
during the year. The institutional review boards of Massachu-
setts General Hospital (Boston, MA) and the University of
Tokyo (Tokyo, Japan) approved this study.
Study Participants
All hospitalizations between 2001 and 2011 for patients aged
30 years or older with principal diagnosis of AMI were
included in this study. We excluded patients with the hospital
length of stay of zero (LOS) because they may have resulted
from coding errors, our interest was in ordinary AMI patients
who stayed longer than 1 day and the characteristics of the
AMI patients with zero LOS (eg, those who were transferred to
other institutions or who died within 24 hours of admission)
are likely to be different from them, and technically we could
not calculate the geometric mean of LOS when the data
include zeros. We identified an AMI hospitalization using the
International Classification of Diseases—Ninth Revision, Clin-
ical Modification (ICD-9-CM) primary discharge diagnosis code
for AMI (ICD-9-CM codes 410.x0 and 410.x1). We excluded
ICD-9-CM codes 410.x2 which represents an AMI episode of
care following the initial episode (eg, hospital transfers). The
primary unit of analysis was a patient hospitalization, counted
at discharge. We further classified the hospitalizations into 2
groups by the type of AMI: STEMI and NSTEMI. STEMI was
identified by using codes for AMIs of the anterolateral wall
(ICD-9-CM codes of 410.00 and 410.01), other anterior wall
(410.10 and 410.11), inferolateral wall (410.20 and 410.21),
inferoposterior wall (410.30 and 410.31), other inferior wall
(410.40 and 410.41), other lateral wall (410.50 and 410.51),
true posterior wall (410.60 and 410.61), or other specified
sites (410.80 and 410.81). NSTEMI was identified using codes
for subendocardial infarction (410.70 and 410.71) or AMI of
unspecified site (410.90 and 410.91). Because each dis-
charge has a unique primary discharge diagnosis code, all
included in our sample were classified as either STEMI or
NSTEMI. We also collected information about the intervention
received (percutaneous coronary intervention [PCI] and cor-
onary artery bypass grafting [CABG]) using the ICD-9-CM
procedure code. We considered discharges as having under-
gone PCI during hospitalization when they had procedure
codes of percutaneous transluminal coronary angioplasty or
coronary atherectomy (00.66, 36.01, 36.02, 36.05), insertion
of non-drug-eluting coronary artery stent(s) (36.06), or
insertion of drug-eluting coronary artery stent(s) (36.07). We
considered discharges as having undergone CABG during
hospitalization when they had procedure codes of bypass
anastomosis for heart revascularization (36.1x). Patients
“without intervention” were defined as those having neither
of PCI nor CABG during hospitalizations.
Outcome Measures
Primary outcomes of this study were the all-cause in-hospital
mortality and costs per hospitalization for AMI. Secondary
outcome measures included total costs per hospitalization
and hospital length of stay (LOS). Although hospital charges
per discharge (physician fees not included) were available in
NIS, actual cost data were not available in NIS. Therefore, we
used hospital-specific cost-to-charge ratios (CCRs) provided
by HCUP and converted charges into costs.20 When hospital-
specific CCRs were not available, we used group average
CCRs instead. The hospital accounting reports collected by
the Centers for Medicare and Medicaid Services were used to
obtain CCR information. The cases without any CCR informa-
tion were excluded from the analyses (missing data in <10% of
eligible cases), and the data were appropriately reweighted to
calculate the national estimates of the costs, as suggested by
the HCUP.20 To facilitate direct comparisons between years
for hospital costs, we converted all hospital costs to 2011 US
dollars using the Consumer Price Index (CPI).21
Other Variables
We collected information about both patient- and hospital-level
characteristics that are associated with the mortality and
costs of care, and used them as adjustment variables in our
regression models. The collected patient characteristics
include age at admission, gender, primary health insurance
type, hospitalization source, and comorbidities. We did not
include race/ethnicity in our analyses because the data were
missing for quite a large portion of units (26% missing in 2001),
and the race/ethnicity information in the HCUP data was
considered to be missing not at random. Age at admission was
categorized by 10 years. Health insurance type was catego-
rized as Medicaid, Medicare, private, or others including the
uninsured. Hospitalization source was dichotomized into
elective hospitalization or not. Comorbidities were assessed
using Clinical Classifications Software (CCS) developed by
AHRQ based on the methods by Elixhauser et al,22 and all
comorbidities included in the Elixhauser Comorbidity Index
were adjusted except congestive heart failure. The hospital
factors include bed size, hospital ownership, hospital region,
and a category made of urban/rural distinction and teaching
status. With regard to hospital characteristics, bed size was
categorized as small, medium, or large based on the number of
hospital beds using cut-off points specific to the hospital’s
DOI: 10.1161/JAHA.114.001445 Journal of the American Heart Association 2
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region, location, and teaching status. Ownership of the
hospital was grouped as government nonfederal, private non-
profit, and private investor-own. Hospital regions consist of
Northeast, Midwest, South, and West. Hospital location (urban
or rural) and teaching status were jointly categorized as rural,
urban non-teaching, and urban teaching.
Statistical Analyses
All analyses used SAS-callable SUDAAN, version 11.0
(Research Triangle Institute, Research Triangle Park, NC) to
obtain appropriate variance estimations that accounted for the
complex survey sampling design. We calculated AMI hospital-
ization incidence rates (the number of estimated hospitaliza-
tions per 1000 populations) using the population estimates.23
Poisson regression was used to calculate P values for the trend
(Ptrend) for the incidence rates. The proportion of STEMI among
all AMI hospitalizations was calculated, and the time trend was
assessed using the logistic regression models using the year
indicator as continuous variable. Weighted estimates of
patient and hospital characteristics for each year were
described for all AMI discharges, and also separately for
STEMI and NSTEMI cases. We also calculated the proportion of
cases with PCI and CABG for STEMI and NSTEMI hospitaliza-
tions. Logistic regression analyses with year variable used as
continuous were used to assess the time trends of the
proportions of PCI and CABG use.
Next, we examined the trends of in-hospital mortality
stratified by the type of AMI and the intervention received. We
classified AMI hospitalizations into 6 groups: (1) STEMI with
PCI, (2) STEMI with CABG, (3) STEMI without intervention, (4)
NSTEMI with PCI, (5) NSTEMI with CABG, and (6) NSTEMI
without intervention. We evaluated both unadjusted and
adjusted time trend by fitting logistic regression models with
the year indicator used as a continuous variable. The patient-
and hospital-level characteristics adjusted in the evaluation of
the adjusted association are listed in Other Variables. In order
to account for the clustering of the hospitalizations at hospital-
level, we used generalized estimating equations (GEE) with
logistic link function. An exchangeable working correlation
structure was selected, as this correlation matrix is most
widely used for health data and any permutation is valid.24
We also examined the temporal trends of hospital costs
per hospitalization. Because hospital costs per hospitalization
were not normally distributed, we log-transformed the costs
per hospitalization, took the average of the logarithmic values,
and then back-transformed the average, calculating a
geometric mean. We then constructed linear regression
models with log-transformed costs as the outcome variable
to estimate the percent changes of hospital costs per
hospitalization from 2001. We used similar methods for the
analysis of the temporal trends of LOS.
We also estimated aggregate national hospital costs on
AMI hospitalizations in the United States adjusted for CPI by
means of aggregating all the CPI-adjusted costs of all AMI
hospitalizations for each year.
Results
From 2001 through 2011, we identified a total of 1 456 154
patient discharges of AMI in the United States, corresponding to
a weighted estimate of 7 135 592 discharges. Characteristics
of the hospitalized patients with AMI over the 11-year period are
presented in Table 1. There was missing information for each
demographic variable as follows: 158 (0.01%) missing gender,
2608 (0.2%) missing payer, 139 082 (9.6%) missing type of
admission, 5969 (0.4%) missing bed size and location/teaching
status, and 17 799 (1.2%) missing ownership of hospital. There
was no missing value with regard to age and hospital region.
Incidence
The overall rate of AMI hospitalizations declined significantly
during the study period (4.5 per 1000 populations in 2001 to
3.2 per 1000 populations in 2011; 29% decrease;
Ptrend<0.001, Table 1). The proportion of STEMI among AMI
hospitalizations also decreased (40.2% in 2001 to 26.9% in
2011; 33% decrease; Ptrend<0.001). In more recent years,
patients hospitalized for AMI were more likely to be male, less
likely to be admitted as elective hospitalization, more likely to
be admitted to private investor-owned hospitals, and less
likely to be admitted to rural hospitals.
Use of PCI and CABG for AMI
The weighted proportion of PCI and CABG use was calculated
and shown in Table 2. During the study period, the use of PCI
increased significantly for both the STEMI (75% increase;
Ptrend<0.001) and NSTEMI patients (54% increase; Ptrend<
0.001). By contrast, the CABG use decreased for both STEMI
(39% decrease; Ptrend<0.001) and NSTEMI (14% decrease;
Ptrend=0.005). Both the proportion of PCI use and the rate of
increase in PCI use among STEMI hospitalizations were greater
compared with those among NSTEMI hospitalizations.
In-Hospital Mortality
We observed differential time trends of unadjusted in-hospital
mortality by the type of AMI and the type of intervention
(Table 3). For STEMI, in-hospital mortality increased among
those who did not receive intervention (20% increase,
Ptrend<0.001). On the other hand, the mortality did not change
significantly among those who received PCI (3.5% increase,
Ptrend=0.12) or CABG (1.6% decrease, Ptrend=0.14). Among
DOI: 10.1161/JAHA.114.001445 Journal of the American Heart Association 3
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NSTEMI cases, in-hospital mortality decreased significantly,
especially among those who did not receive intervention (29%
decrease; Ptrend<0.001) and those who underwent CABG (41%
decrease; Ptrend<0.001).We did not find a systematic pattern as
to the in-hospital mortality among NSTEMI patients who
received PCI (16% decrease, Ptrend=0.29).
Table 2. Weighted Proportion of STEMI/NSTEMI Hospitalizations by Type of Intervention (Only PCI, CABG, and Without
Intervention), 2001–2011
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Ptrend*Unweighted n Weighted % Among STEMI or NSTEMI
STEMI
Only PCI 285 799 43.7% 46.7% 50.3% 53.7% 57.9% 62.3% 65.4% 69.7% 73.0% 75.3% 76.6% <0.001
CABG 46 303 10.9% 11.1% 10.6% 10.3% 9.7% 9.9% 9.2% 8.2% 8.2% 6.7% 6.7% <0.001
Without intervention 152 689 45.4% 42.2% 39.2% 36.0% 32.4% 27.8% 25.4% 22.1% 18.8% 18.0% 16.8% <0.001
NSTEMI
Only PCI 278 784 22.0% 22.6% 24.6% 27.2% 28.9% 31.3% 29.8% 30.8% 33.0% 32.6% 33.9% <0.001
CABG 95 007 10.5% 10.7% 10.2% 9.8% 9.3% 10.1% 9.4% 9.3% 9.9% 9.3% 9.0% 0.005
Without intervention 597 572 67.6% 66.7% 65.2% 63.0% 61.9% 58.6% 60.9% 59.9% 57.2% 58.1% 57.1% <0.001
CABG indicates coronary artery bypass grafting; CI, confidence interval; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation
myocardial infarction.
*Ptrend was calculated using logistic regression models with a continuous year variable as the independent variable.
Table 3. Unadjusted Trend of in-Hospital Mortality and Geometric Means of Hospital Costs, and Hospital Length of Stay, by
STEMI/NSTEMI and PCI/CABG Use
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Ptrend*
In-hospital mortality, %
STEMI with only PCI 3.40 3.33 3.12 3.05 3.21 3.14 3.32 3.48 3.41 3.35 3.52 0.12
STEMI with CABG 5.79 5.23 5.41 5.43 6.23 5.13 4.92 5.04 5.15 4.53 5.70 0.14
STEMI without intervention 12.43 12.96 13.01 12.92 13.18 12.94 14.52 14.57 15.21 14.51 14.91 <0.001
NSTEMI with only PCI 1.73 1.69 1.47 1.59 1.48 1.52 1.58 1.64 1.71 1.52 1.45 0.29
NSTEMI with CABG 4.97 4.77 4.66 4.31 4.30 3.72 3.96 3.59 3.60 2.97 2.91 <0.001
NSTEMI without intervention 8.87 8.79 8.64 8.49 8.05 7.57 6.88 6.96 6.47 6.33 6.26 <0.001
Hospital costs, dollars in 2011
STEMI with only PCI 17 182 18 230 18 820 20 605 20 661 20 266 19 729 19 917 19 661 19 782 19 614 <0.001
STEMI with CABG 36 923 38 635 40 097 41 992 43 968 42 777 44 962 44 919 45 282 45 647 45 935 <0.001
STEMI without intervention 8746 9207 9196 9368 9077 9242 9660 9917 9969 10,183 10,246 <0.001
NSTEMI with only PCI 15 636 16 519 17 776 19 983 19 874 19 342 18 532 18 954 18 607 18 766 18 733 <0.001
NSTEMI with CABG 35 700 36 456 39 278 41 338 42 319 40 959 42 746 41 885 42 428 42 652 43 182 <0.001
NSTEMI without intervention 7837 8220 8553 8859 8701 8866 8698 8771 8627 8617 8474 <0.001
Hospital length of stay, days
STEMI with only PCI 3.57 3.56 3.50 3.46 3.37 3.29 3.27 3.22 3.19 3.14 3.07 <0.001
STEMI with CABG 9.42 9.38 9.39 9.33 9.52 9.34 9.57 9.62 9.55 9.31 9.31 0.69
STEMI without intervention 3.47 3.51 3.44 3.43 3.39 3.37 3.43 3.48 3.48 3.40 3.32 0.09
NSTEMI with only PCI 3.14 3.12 3.21 3.17 3.04 2.94 2.85 2.88 2.91 2.90 2.86 <0.001
NSTEMI with CABG 10.03 9.86 10.09 10.44 10.45 10.15 10.46 10.31 10.25 9.95 10.31 0.22
NSTEMI without intervention 3.84 3.81 3.85 3.78 3.75 3.68 3.55 3.60 3.48 3.39 3.27 <0.001
CABG indicates coronary artery bypass grafting; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.
*Ptrend was calculated using logistic regression models for mortality and linear regression models for continuous outcome variables.
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After controlling for both patient- and hospital-level
characteristics, we found that in-hospital mortality improved
dramatically among NSTEMI patients regardless of the type of
treatments they received. The patient outcomes improved for
those patients who received PCI (OR 0.68, 95% CI 0.56 to
0.83), CABG (OR 0.57, 95% CI 0.45 to 0.72), or without
intervention (OR 0.61, 95% CI 0.57 to 0.65) (Table 4 and
Figure 1). As for STEMI patients, adjusted in-hospital mortality
improved for those who received PCI (OR 0.83, 95% CI 0.73 to
0.94), but no significant improvement was seen for those who
underwent CABG (OR 0.92, 95% CI 0.72 to 1.19) or those
without intervention (OR 0.98, 95% CI 0.88 to 1.09).
Hospital Costs per Hospitalization
The trends in hospital costs were assessed using unadjusted
(Table 3) and adjusted analyses (Table 5 and Figure 2). From
2001 to 2011, the hospital costs increased significantly
across the subgroups. In the adjusted analyses, the increases
in geometric means in 2011 compared with those in 2001
were larger among those with PCI or CABG than among those
without intervention. The largest increase was found among
STEMI hospitalizations that underwent CABG (20.7% increase;
95% CI, 14.6% to 27.1%).
Length of Stay
The LOS of AMI hospitalizations decreased, especially among
those with PCI or those without intervention (eg, STEMI with
PCI: 18.3% decrease, 95% CI, 20.5% to 16.1%). The
decrease of LOS among those with CABG appeared smaller,
and the trend was not statistically significant among NSTEMI
hospitalization that underwent CABG (1.2% decrease, 95% CI,
4.5% to 2.3%) (Table 6).
Aggregate National Hospital Costs
The aggregated national hospital costs in the United States are
illustrated in Table 7. After adjusting for the inflation, hospital
costs for AMI hospitalizations decreased nationally from $12.4
billion in 2001 to $11.3 billion in 2011 (9% decrease).
Discussion
By using a large, nationally representative database of US
hospitalizations from 2001 to 2011, we found that differential
time trends of in-hospital mortality and hospital costs by the
type of AMI and the type of intervention received. Most
notably, adjusted in-hospital mortality declined significantly
for NSTEMI regardless of the type of intervention received. In
contrast, among STEMI patients, the improvement in in-
hospital mortality was statistically significant only for those
who underwent PCI, and no improvement was observed for
those who received CABG or those without any intervention.
Hospital costs increased significantly for those who received
intervention; the rate of increase in hospital costs was most
prominent among those patients who received CABG.
Previous studies have investigated the temporal trends of
mortality and hospital costs for AMI patients. An analysis using
the Kaiser Permanente Northern California dataset reported
that 30-day mortality of NSTEMI patients decreased, whereas
the mortality of STEMI patients did not improve.4 Their sample
was not a nationally representative sample of the US popula-
tion, and the patients who underwent PCI and those who
received CABG were not assessed separately. They also did not
evaluate the cost data. Movahed et al examined the in-hospital
mortality for STEMI and NSTEMI patients using the HCUP NIS
datasets,10,11,15,16 but they did not stratify their analysis by the
intervention received. Zhao and colleagues compared hospital
costs by the intervention performed using a dataset of
commercially insured individuals in the United States.25 Their
data were again not a nationally representative sample, and
they did not look into the time trends of hospital costs. To the
best of our knowledge, this is the first study showing that the
trends of in-hospital mortality and hospital costs differ by type
of AMI and intervention received during hospitalization.
There are multiple possible reasons for the observed
decrease in mortality for NSTEMI without intervention and
NSTEMI who underwent CABG. Consistent improvement in
primary and secondary prevention of AMI—eg, appropriate
prescription of aspirin, b-blockers, and statins26—may affect
.
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Figure 1. Temporal trends of in-hospital mortality for acute
myocardial infarction hospitalizations in the United States by ST-
elevation/non-ST-elevation and percutaneous coronary interven-
tion/cardiac bypass graft stenting use. Year 2001 was used as
the reference. CABG indicates coronary artery bypass grafting;
PCI, percutaneous coronary intervention; STEMI, non-ST-elevation
myocardial infarction.
DOI: 10.1161/JAHA.114.001445 Journal of the American Heart Association 8
Mortality and Costs for AMI Hospitalizations Sugiyama et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Ta
bl
e
5.
Ad
ju
st
ed
*
Tr
en
d
of
G
eo
m
et
ric
M
ea
ns
of
H
os
pi
ta
lC
os
ts
by
ST
EM
I/
N
ST
EM
I
an
d
PC
I/
C
AB
G
U
se
n
(%
)†
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
O
dd
s
Ra
tio
(9
5%
C
I)
C
om
pa
re
d
to
20
01
ST
EM
Iw
ith
on
ly
PC
I
23
4,
62
7
(8
2.
1%
)
Re
f.
+
7.
0%
(2
.6
to
11
.6
%
)
+
10
.9
%
(5
.2
to
17
.0
%
)
+
18
.6
%
(1
2.
4
to
25
.2
%
)
+
19
.8
%
(1
4.
2
to
25
.6
%
)
+
17
.5
%
(1
2.
3
to
23
.0
%
)
+
12
.3
%
(7
.1
to
17
.7
%
)
+
14
.4
%
(9
.2
to
19
.9
%
)
+
11
.2
%
(6
.4
to
16
.3
%
)
+
7.
3%
(1
.5
to
13
.5
%
)
+
10
.0
%
(4
.9
to
15
.3
%
)
ST
EM
Iw
ith
CA
BG
36
,6
82
(7
9.
2%
)
Re
f.
+
7.
6%
(3
.4
to
12
.0
%
)
+
14
.4
%
(8
.6
to
20
.5
%
)
+
16
.7
%
(1
1.
0
to
22
.6
%
)
+
21
.4
%
(1
5.
7
to
27
.5
%
)
+
20
.4
%
(1
4.
5
to
26
.6
%
)
+
23
.7
%
(1
8.
0
to
29
.8
%
)
+
25
.3
%
(1
9.
2
to
31
.7
%
)
+
22
.1
%
(1
6.
1
to
28
.3
%
)
+
20
.0
%
(1
2.
4
to
28
.2
%
)
+
20
.7
%
(1
4.
6
to
27
.1
%
)
ST
EM
Iw
ith
ou
t
in
te
rv
en
tio
n
11
7,
75
6
(7
7.
1%
)
Re
f.
+
4.
8%
(1
.9
to
7.
8%
)
+
4.
1%
(0
.9
to
7.
3%
)
+
3.
7%
(0
.1
to
7.
5%
)
+
1.
9%
(
1.
4
to
5.
2%
)
+
1.
7%
(
1.
7
to
5.
3%
)
+
2.
3%
(
1.
6
to
6.
4%
)
+
5.
0%
(1
.1
to
9.
0%
)
+
0.
9%
(
3.
5
to
5.
6%
)
1
.8
%
(
6.
4
to
3.
0%
)
+
1.
9%
(
2.
7
to
6.
7%
)
NS
TE
M
Iw
ith
on
ly
PC
I
23
1,
90
0
(8
3.
2%
)
Re
f.
+
7.
3%
(2
.2
to
12
.6
%
)
+
16
.2
%
(9
.2
to
23
.6
%
)
+
25
.0
%
(1
7.
0
to
33
.7
%
)
+
24
.2
%
(1
7.
7
to
31
.2
%
)
+
23
.6
%
(1
7.
4
to
30
.0
%
)
+
15
.7
%
(1
0.
0
to
21
.7
%
)
+
18
.3
%
(1
2.
8
to
24
.1
%
)
+
15
.0
%
(9
.3
to
20
.9
%
)
+
9.
3%
(2
.1
to
17
.0
%
)
+
10
.5
%
(5
.0
to
16
.3
%
)
NS
TE
M
Iw
ith
CA
BG
77
,5
78
(8
1.
7%
)
Re
f.
+
7.
4%
(3
.6
to
11
.4
%
)
+
14
.6
%
(9
.1
to
20
.3
%
)
+
16
.3
%
(1
1.
3
to
21
.6
%
)
+
19
.3
%
(1
4.
5
to
24
.2
%
)
+
18
.7
%
(1
3.
1
to
24
.6
%
)
+
20
.6
%
(1
5.
5
to
25
.8
%
)
+
23
.0
%
(1
8.
1
to
28
.1
%
)
+
20
.1
%
(1
5.
3
to
25
.1
%
)
+
15
.4
%
(9
.1
to
22
.0
%
)
+
18
.4
%
(1
3.
3
to
23
.7
%
)
NS
TE
M
Iw
ith
ou
t
in
te
rv
en
tio
n
48
4,
89
4
(8
1.
1%
)
Re
f.
+
5.
4%
(2
.7
to
8.
1%
)
+
9.
8%
(6
.7
to
13
.0
%
)
+
9.
6%
(6
.5
to
12
.8
%
)
+
9.
3%
(6
.3
to
12
.3
%
)
+
7.
6%
(4
.6
to
10
.8
%
)
+
4.
5%
(0
.9
to
8.
3%
)
+
6.
4%
(3
.4
to
9.
4%
)
+
1.
8%
(
1.
4
to
5.
1%
)
1
.7
%
(
5.
7
to
2.
4%
)
+
0.
5%
(
2.
6
to
3.
7%
)
C
AB
G
in
di
ca
te
s
co
ro
na
ry
ar
te
ry
by
pa
ss
gr
af
tin
g;
C
I,
co
nfi
de
nt
ia
li
nt
er
va
l;
N
ST
EM
I,
no
n-
ST
-e
le
va
tio
n
m
yo
ca
rd
ia
li
nf
ar
ct
io
n;
PC
I,
pe
rc
ut
an
eo
us
co
ro
na
ry
in
te
rv
en
tio
n;
Re
f,
re
fe
re
nc
e;
ST
EM
I,
ST
-e
le
va
tio
n
m
yo
ca
rd
ia
l
in
fa
rc
tio
n.
*A
dj
us
te
d
fo
r
pa
tie
nt
-le
ve
lc
ha
ra
ct
er
is
tic
s
(ie
,
ag
e
ca
te
go
ry
,
ge
nd
er
,p
rim
ar
y
pa
ye
r,
ad
m
is
si
on
so
ur
ce
,a
nd
al
lc
om
or
bi
di
ty
va
ria
bl
es
fr
om
El
ix
ha
us
er
C
om
or
bi
di
ty
In
de
x
bu
t
th
e
va
ria
bl
e
fo
r
co
ng
es
tiv
e
he
ar
t
fa
ilu
re
)
an
d
ho
sp
ita
l-l
ev
el
ch
ar
ac
te
ris
tic
s
(h
os
pi
ta
lb
ed
si
ze
,
ow
ne
rs
hi
p
of
th
e
ho
sp
ita
l,
ho
sp
ita
lr
eg
io
ns
,
an
d
th
e
va
ria
bl
e
fo
r
ho
sp
ita
ll
oc
at
io
n
an
d
te
ac
hi
ng
-s
ta
tu
s)
in
m
ul
tip
le
re
gr
es
si
on
s
st
ra
tifi
ed
by
ST
EM
I/
N
ST
EM
I
an
d
PC
I/
C
AB
G
us
e.
†
N
um
be
r
of
ob
se
rv
at
io
ns
in
ea
ch
re
gr
es
si
on
an
d
th
e
pr
op
or
tio
n
in
th
e
su
bg
ro
up
w
as
pr
es
en
te
d.
Th
e
nu
m
be
rs
in
co
st
an
al
ys
es
w
er
e
fe
w
er
th
an
ot
he
rs
du
e
to
th
e
m
is
si
ng
ne
ss
w
ith
re
ga
rd
to
co
st
-c
ha
rg
e
ra
tio
;m
od
ifi
ed
w
ei
gh
tw
as
us
ed
fo
rc
os
t
an
al
ys
es
co
ns
id
er
in
g
th
e
m
is
si
ng
ne
ss
.
DOI: 10.1161/JAHA.114.001445 Journal of the American Heart Association 9
Mortality and Costs for AMI Hospitalizations Sugiyama et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
mortality especially among these populations. Alternatively,
patients with NSTEMI in more recent study periods may
include patients diagnosed only by highly sensitive troponin
but with less severe myocardial damage.4,14 This could have
led to the observed lower mortality in NSTEMI in recent years.
Additionally, the indication of CABG for NSTEMI may have
changed over time and become highly selective, thereby
leading to lower mortality.
The increased hospital costs among AMI patients may
come from the increasing trend in general medical spend-
ing.27 But the costs of devices and procedures supposedly
increased faster than general medical spending considering
the prominent increase of costs among those who received
intervention. We observed that LOS was shortened for
patients with PCI and for patients with CABG (albeit slowly)
during the study period; however, the increased costs per unit
of intervention might have outweighed the effect of shortened
LOS on total costs per hospitalization.
At the national level, aggregate national hospital costs for
AMI hospitalizations decreased by 9% during the study period
(these figures did not include physician fees). The drastically
decreased incidence of AMI hospitalizations was mostly offset
by the increased hospital costs per hospitalization, especially
for AMI with intervention. Curbing the increasing hospital costs
per hospitalization may be critical to reduce total health
expenditure spent on the treatment of AMI in the United States.
Our study has several limitations. First, as with any studies
using administrative data, errors in recording diagnoses are
possible. However, HCUP data are shown to be relatively
accurate, and widely used to estimate diagnoses, procedures,
and healthcare expenditures.28,29 Second, due to advances in
technology related to PCI, severe AMI cases who would have
been treated with CABG a decade ago, are more likely to be
treated by PCI in recent years. This does not affect a consistent
improvement across the treatment type among NSTEMI
patients, but it may explain non-significant improvement in
mortality among the STEMI patients who underwent CABG.
Third, the HCUP NIS contains discharge-level records, not
patient-level records, and thus we were unable to identify
multiple hospitalizations for each patient. Fourth, the lack of
patient identifiers in the NIS precluded us from using other
mortality measures such as 30-day mortality. Previous studies
using data from MIDAS in New Jersey found that in-hospital
declines in mortality were observed but the post-discharge AMI
mortality in fact increased.30 Our findings cannot be extrapo-
lated to the other outcome measures of the AMI patients, but
we believe that the national estimates of the in-hospital
mortality over time are valuable information for clinicians and
policy makers. Fifth, although we adjusted for both patient- and
hospital-level characteristics in evaluating the change in in-
hospital mortality and hospital costs, theremay be unmeasured
time-varying confounders. Sixth, the HCUP charges do not
include physician fees, thereby leading to underestimation of
total costs per AMI hospitalization. However, it is unlikely the
proportion of physician fees out of total costs has increased
over time differently across the type of AMI and the intervention
received; therefore, this may not confound our findings. Lastly,
due to the nature of HCUP NIS dataset, costs of care after
discharges were unknown. Likosky and colleagues showed
more rapid increase in expenditures occurring after discharge
using data of fee-for-service Medicare beneficiaries.31 Addi-
tional data and analyses are needed to obtain broader
understanding about financial burden of AMI incidence.
This study has several important implications. Because AMI
continues to be one of the major public health burdens in our
healthcare system, the rising spending for AMI hospitaliza-
tions should encourage policy makers and health services
researchers to develop more cost-effective approaches for the
management of AMI. Identification and development of
strategies for reducing the costs of AMI hospitalizations
accompanied by interventions (ie, PCI and/or CABG) may be
an effective approach to reducing the net financial burden of
AMI on healthcare systems. For clinicians, the observed
decline in the mortality in patients with NSTEMI is encour-
aging and supports the prior optimism that AMI morbidity and
mortality can be prevented.
Conclusions
In summary, using a large nationally representative database of
US hospitalizations in 2001–2011, we found that in-hospital
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Figure 2. Temporal trends of percent change of hospital costs
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mortality decreased significantly for NSTEMI regardless of the
type of treatment they received. By contrast, we found
significant improvement only for STEMI with PCI; no significant
improvement was observed for STEMI patients who received
CABG and those without intervention. Hospital costs increased
significantly for those who received intervention, and the rate of
increase in hospital costs was most prominent among those
patients who underwent CABG. These non-uniform temporal
trendsmay be informative for designing effective health policies
that reduce the health and economic burdens of AMI in the
United States.
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